As advances in next generation sequencing technology becomes increasingly important in treating adult cancers, the same advances are equally important in managing treatment for pediatric cancer patients. For example, recent work by researchers at the University of Michigan on the Peds-MiOncoSeq study found that identifying mutations present in tumor tissue can lead to changes in treatment recommendations.